Kidney patients get first look at new obesity drug
NCT ID NCT07443059
First seen Mar 10, 2026 · Last updated Jun 20, 2026 · Updated 14 times
Summary
This early-stage study tests a single dose of Zovaglutide (ZT002), an experimental drug for overweight and obesity, in 40 adults with varying levels of kidney function. Researchers will measure how the drug moves through the body and check for side effects. The goal is to understand if kidney problems change how the drug works, not to treat kidney disease or cause weight loss.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT , OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sichuan Provincial People's Hospital
RECRUITINGChengdu, Sichuan, 250014, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital Of Shandong First Medical Unversity
RECRUITINGJinan, Shandong, 250014, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Xiamen University
NOT_YET_RECRUITINGXiamen, Fujian, 361003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Zovaglutide (ZT002 injection)
What this could lead to
If successful, this could help determine safe dosing of Zovaglutide for people with kidney problems who are overweight or obese.
What could go wrong
This is a very early Phase 1 study with only 40 participants. It focuses on drug levels and safety, not on weight loss or kidney improvement. Results may not apply to broader populations.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.